Coherus Oncology, Inc. (CHRS)
| Market Cap | 272.97M |
| Revenue (ttm) | 42.17M |
| Net Income (ttm) | 168.02M |
| Shares Out | 154.22M |
| EPS (ttm) | 1.43 |
| PE Ratio | 1.23 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 624,128 |
| Open | 1.792 |
| Previous Close | 1.840 |
| Day's Range | 1.755 - 1.855 |
| 52-Week Range | 0.710 - 2.616 |
| Beta | 1.04 |
| Analysts | Strong Buy |
| Price Target | 5.51 (+211.3%) |
| Earnings Date | May 7, 2026 |
About CHRS
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27. It also develops CHS-114, an investigational human afucosylated IgG1 monoclonal antibo... [Read more]
Financial Performance
In 2025, Coherus Oncology's revenue was $42.17 million, an increase of 59.81% compared to the previous year's $26.39 million. Earnings were $168.02 million, an increase of 489.41%.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for CHRS stock is "Strong Buy." The 12-month stock price target is $5.51, which is an increase of 211.30% from the latest price.
News
Coherus Oncology Transcript: The Citizens Life Sciences Conference 2026
The company has transformed into a focused oncology innovator, advancing LOQTORZI, tagmokitug, and casdozokitug across multiple cancer indications. Strong sales growth, strategic collaborations, and promising clinical data position it for significant market expansion and pivotal trial decisions in 2026.
Coherus Oncology Earnings Call Transcript: Q4 2025
Transformation to a focused oncology company drove LOQTORZI sales up 113% year-over-year, with debt reduced by over 90%. Multiple clinical trials for tagmokitug and casdozokitug are underway, with key data readouts expected from mid-2026.
Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update
– LOQTORZI® net revenue more than doubled to $40.8 million in 2025 from $19.1 million in 2024 – – Reduced secured and convertible debt by 90% from $480 million to $38.8 million over 2024-2025 – – $172...
Coherus Oncology Transcript: TD Cowen 46th Annual Health Care Conference
Management highlighted a successful transformation to oncology, major debt reduction, and strong commercial momentum for LOQTORZI. Pipeline assets tagmokitug and casdozokitug show promising clinical data and broad partnering opportunities, with key data readouts expected mid-year.
Coherus Oncology to Report Full Year and Fourth Quarter 2025 Financial Results on March 9, 2026
REDWOOD CITY, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today announced that its full year and fourth quarter 2025 financial results will be released after mark...
Coherus Oncology to Participate in Upcoming Investor Conferences
REDWOOD CITY, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS) today announced that senior management will be presenting during upcoming conferences. The presentations w...
Coherus Oncology, Inc. Announces Closing of Public Offering of Common Stock
–The Offering was led by healthcare-dedicated investors including Janus Henderson Investors, HBM Healthcare Investments and Samsara BioCapital–
Coherus Oncology, Inc. Announces Pricing of Public Offering of Common Stock
REDWOOD CITY, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (“Coherus” or the “Company”) (NASDAQ: CHRS), today announced the pricing of an underwritten public offering of 28,600,000...
Coherus Oncology Transcript: 44th Annual J.P. Morgan Healthcare Conference
The conference highlighted a strategic transformation, with major divestitures funding a robust oncology pipeline. LOQTORZI sales are exceeding targets, while tegmokitug and casdozokitug show strong clinical promise, with pivotal data readouts expected in 2026.
Coherus Management to Present at the 44th Annual J.P. Morgan Healthcare Conference
REDWOOD CITY, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS) today announced that senior management will present at the 44th Annual J.P. Morgan Healthcare Conference o...
Coherus Oncology Announces Publication in Molecular Cancer Therapeutics Highlighting the Strong Pharmacology of Investigational CCR8 Antibody Tagmokitug (CHS-114)
-Coherus Oncology formally introduces non-proprietary name: tagmokitug- -Publication shows picomolar affinity for CCR8 with no off-target binding and proof-of- mechanism in preclinical and clinical s...
Coherus Oncology Transcript: Biotech Discovery Series
The event highlighted a strategic pivot to immuno-oncology, with promising data for Casdozokitug in HCC and Tagmokitug in multiple solid tumors. Key 2026 data readouts are expected, and Toripalimab continues to show strong survival benefits and commercial progress.
Coherus Announces Six-Year JUPITER-02 Follow-up Results Showing LOQTORZI® plus Chemotherapy Nearly Doubles Median Overall Survival in Nasopharyngeal Carcinoma
-6 Years Long-term survival data reinforce potential benefit to patient survival in treating recurrent or metastatic nasopharyngeal carcinoma with LOQTORZI in combination with chemotherapy - -6 Years ...
Coherus Oncology Transcript: Jefferies London Healthcare Conference 2025
The conference highlighted a robust oncology pipeline with LOQTORZI as a commercial anchor and innovative assets like CHS-114 and casdozokitug advancing in multiple cancer indications. Strategic deals, global rights, and strong early clinical data position the company for significant growth.
Coherus Oncology Transcript: UBS Global Healthcare Conference 2025
Management highlighted a focused oncology strategy, robust pipeline progress, and strong financials. Key assets Toripalimab, CHS-114, and Casdozokitug are advancing in multiple indications, with pivotal data and business development catalysts expected over the next 12-18 months.
Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic Antibody
– CHS-114 demonstrated robust and selective depletion of CCR8+ Tregs as well as favorable immune remodeling in tumor tissue from head and neck squamous cell carcinoma (HNSCC) patients –
Coherus Oncology Earnings Call Transcript: Q3 2025
Q3 saw strong LOQTORZI revenue growth and significant progress in the oncology pipeline, with robust financial discipline and a strengthened balance sheet. Multiple clinical data readouts are expected in 2026, supporting long-term growth and partnership opportunities.
Coherus Oncology Reports Third Quarter 2025 Financial Results and Provides Business Update
– CHS-114, a highly selective Treg depleter, clinical program expanded to include colorectal cancer – – Q3 2025 ending cash, cash equivalents and marketable securities of $191.7 million – – LOQTORZI® ...
Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer
– Responsible for Corporate Development, Investor Relations, Government Affairs – REDWOOD CITY, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today announced that A...
Coherus Oncology to Report Third Quarter 2025 Financial Results on November 6, 2025
REDWOOD CITY, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today announced that its third quarter 2025 financial results will be released after market close on Thur...
4 Biotechnology Stocks Lead Momentum Gains Amid Strong Technicals
Among the recent momentum standouts in the biotechnology sector, four stocks have drawn considerable investor attention, entering the top 10th percentile of momentum-ranked stocks based on decisive we...
Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
– CHS-114, an anti-CCR8 cytolytic antibody, will also be featured in SITC's upcoming webinar series “Targets for Cancer IO: A Deep Dive” on October 22, 2025 – – CHS-114, an anti-CCR8 cytolytic antibod...
Coherus Oncology Transcript: UBS Virtual Oncology Day
The event highlighted a robust oncology pipeline with LOQTORZI's differentiated PD-1 profile, strong commercial growth, and a collaborative combination strategy. CHS-114 and casdozokitug programs show promising early data, with key readouts expected in 2025 and 2026.
Coherus Oncology Transcript: H.C. Wainwright 27th Annual Global Investment Conference
The company has fully transitioned to immuno-oncology, focusing on combination therapies and global partnerships. LOQTORZI leads in nasopharyngeal cancer guidelines, with strong academic uptake and targeted community outreach. Key pipeline assets show promising efficacy, with major clinical and business milestones expected in the next year.
Coherus Oncology Transcript: Baird Global Healthcare Conference 2025
A focused oncology company has transformed its portfolio, divesting non-core assets and advancing a pipeline of innovative immunotherapies. Key assets LOQTORZI, CHS-114, and KEZDOSE are progressing in clinical trials, with major data and partnership catalysts expected in the next year.